<DOC>
	<DOCNO>NCT03023384</DOCNO>
	<brief_summary>Create network institution develop country perform AML diagnosis , risk classification , treatment , supportive care follow-up evaluation accord common protocol register data use common clinical research form ( CRFs ) single database available internet .</brief_summary>
	<brief_title>Feasibility Study Intermediate Doses ARA-C With Autologous SCT Consolidation Low/Intermediate-risk AML</brief_title>
	<detailed_description>1 . Compare overall survival disease-free survival patient acute myeloid leukemia classify accord European LeukemiaNet treat participate South American hospital result report developed country . 2 . Compare overall survival disease-free survival patient AML low intermediate risk treat two cycle cytarabine intermediate dose versus one cytarabine cycle dose follow autologous SCT consolidation . The risk establish accord classification European LeukemiaNet . 3 . Create network institution develop country perform AML diagnosis , risk classification , treatment , supportive care follow-up evaluation accord common protocol register data use common clinical research form ( CRFs ) single database available internet 4 . Using National Reference Laboratories , provide cytogenetic molecular method institution participate network , thus allow rapid diagnosis risk stratification AML case accord European LeukemiaNet structure ; 5 . Develop method assess minimal residual disease base flow cytometry adapt local resource capable guide therapeutic decision ; 6 . Determine time interval : ) diagnosis risk group determination ; b ) first cycle consolidation chemotherapy autologous hematopoietic stem cell infusion ; 7 . Determine frequency etiologic agent infection associate treatment , number average duration hospitalization due episode neutropenia ; 8 . Create bank sample bone marrow AML patient different time treatment ; 9 . Determine disease-free survival cumulative incidence rate relapse non-relapse mortality compare chemotherapy alone chemotherapy plus autologous SCT cohort .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>1 . Acute myeloid leukemia ( AML ) diagnosis accord WHO criteria ; 2 . AML treat previously , include : de novo AML secondary myelodysplastic syndrome ; 3 . Absence ( 15 ; 17 ) , PMLRARA rearrangement variant ( acute promyelocytic leukemia diagnosis ) ; 4 . Age great equal 18 year old low equal 65 year old ; 5 . Functional status ECOG 0 2 ; 6 . Signed informed consent ; 7 . Ability follow protocol procedure ; 8 . Willingness use birth control method treatment conclusion ; 9 . Adequate renal liver function : Bilirubin ≤ 1.5x upper limit normality ; AST ALT ≤ 2.5x upper limit normality ; Creatinine ≤ 2.5 mg/dL . 10 . Suitable cardiac function : leave ventricular ejection fraction ≥ 50 % . 1 . Acute promyelocytic leukemia ( APL ) diagnosis accord WHO criteria ; 2 . Diagnosis acute leukemia ambiguous lineage , biphenotypic acute leukemia undifferentiated acute leukemia , accord WHO criteria ; 3 . AML previously treat , except hydroxyurea administration cytoreduction ; 4 . Age great 65 year old low 18 year old ; 5 . Functional status ECOG great 2 ; 6 . Do sign inform consent ; 7 . Inability follow protocol procedure ; 8 . Be fertile female unwilling take birth control method treatment ; 9 . Hypersensitivity drug treatment protocol ; 10 . Positive serology HIV ; 11 . Altered liver renal function relate primary disease ( AML ) : Bilirubin &gt; 1.5x upper limit normality AST ALT &gt; 2.5x upper limit normality Creatinine &gt; 2.5 mg/dL n ) Altered cardiac function , LVEF &lt; 50 %</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Acute Myeloid Leukemia</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>Autologous Stem Cell Transplantation</keyword>
	<keyword>Developing country</keyword>
	<keyword>Clinical network</keyword>
</DOC>